Three years have passed since the FDA announced that it had detected counterfeit versions of the injectable anticancer drug bevacizumab (Avastin®, Genentech, USA) in the US drug-supply chain. Following this discovery, almost 1,000 FDA warning letters were sent to physicians and medical practices in 48 different states and two US territories, as more batches of counterfeit Avastin were uncovered. In response, criminal prosecutions have been pursued against certain distributors and clinicians, and other individuals who trafficked, sold, purchased, and/or administered an unsafe and ineffective treatment while also defrauding the government. Although limited and targeted legal action has been taken, patients potentially affected by this seminal patient safety event have not been appropriately identified. Hence, despite the clear and documented patient-safety and public-health risks posed by the transnational criminal trade in counterfeit medicines, the case study of counterfeit bevacizumab detection in the USA demonstrates the continued lack of information, knowledge, and solutions that would be necessary to protect those who are most affected—the patients. In response, we call for greater investment in multisector, multistakeholder strategies to enhance surveillance for counterfeit medicines and enable improvements in communication of risk information, to better protect patients with cancer.
This is a preview of subscription content
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
US Food and Drug Administration. Counterfeit Version of Avastin in U. S. Distribution [online], (2012).
PMGroup, PMLiVE. Top 50 pharmaceutical products by global sales [online], (2015).
Weaver, C. & Whalen, J. How Fake Cancer Drugs Entered U. S. The Wall Street Journal [online], (2012).
Attaran, A. et al. How to achieve international action on falsified and substandard medicines. BMJ 345, e7381 (2012).
Mackey, T. K. & Liang, B. A. Improving global health governance to combat counterfeit medicines: a proposal for a UNODC–WHO–Interpol trilateral mechanism. BMC Med. 11, 233 (2013).
Mackey, T. K. & Liang, B. A. Oncology and the Internet: regulatory failure and reform. J. Oncol. Pract. 8, 341–343 (2012).
Institute for Safe Medication Practices. Gray Market, Black Heart: Pharmaceutical Gray Market Finds a Disturbing Niche During the Drug Shortage Crisis [online], (2011).
Whalen, J. Egypt Eyed as Possible Source of Fake Avastin. The Wall Street Journal [online], (2012).
Sandle, P. & Acher, J. Denmark's CareMed says shipped fake Avastin unwittingly. Reuters [online], (2012).
US Food and Drug Administration. Letters to Doctors about Risks of Purchasing Medications from Foreign or Unlicensed Suppliers [online], (2012).
Weaver, C., Whalen, J. & Faucon, B. Drug Distributor Is Tied to Imports of Fake Avastin. The Wall Street Journal [online], (2012).
Kuehn, B. M. FDA warning: new batch of fake bevacizumab found. JAMA 309, 864–864 (2013).
US Food and Drug Administration. August 23, 2012: California Man Sentenced for Importing Adulterated Cancer Drugs; Forfeits $1.4 Million & Land Rover Automobile [online], (2012).
US Food and Drug Administration. July 11, 2013: English Citizen Sentenced for Distributing Adulterated and Counterfeit Cancer Drugs [online], (2013).
Department of Justice. United States Attorney's Office, Eastern District of Tennessee. Greeneville Oncologist And Practice Manager Sentenced For Violating Food, Drug And Cosmetic Act: Cancer Clinic Purchased Unapproved Drugs for Three Years [online], (2014).
The Federal Bureau of Investigation, Knoxville Division. Johnson City Physician Sentenced to Serve Two Years in Prison for Violations Related to Unapproved Foreign Drugs [online], (2013).
Weaver, C. U. S. Fake-Drug Probe Puts Spotlight on Role of Doctors. The Wall Street Journal [online], (2012).
US Food and Drug Administration. January 16, 2014: Two Turkish Nationals Indicted for Smuggling Counterfeit Cancer Drug [online], (2014).
Whalen, J. Turkish Drug Exporter Ozay Draws U. S. Scrutiny. The Wall Street Journal [online], (2014).
Department of Justice. United States Attorney's Office, Eastern District of New York. Two Officers Of Long Island Based Company Indicted For Sale.Of $17 Million Worth Of Misbranded Prescription Drugs Including Counterfeit Cancer Drugs [online], (2014).
US Food and Drug Administration. February 16, 2012: Local Cancer Doctor Pleads Guilty to Receiving Misbranded Cancer Drugs Two Californians also Named in Indictment [online], (2012).
Liang, B. A. & Mackey, T. Searching for safety: addressing search engine, website, and provider accountability for illicit online drug sales. Am. J. Law Med. 35, 125–184 (2009).
Institute of Medicine. Countering the Problem of Falsified and Substandard Drugs [online], (2013).
Qureshi, Z. P. et al. Caveat Oncologist: clinical findings and consequences of distributing counterfeit erythropoietin in the United States. J. Oncol. Pract. 8, 84–90 (2012).
Sun, X., Xu, X. & Zhang, X. Counterfeit bevacizumab and endophthalmitis. N. Engl. J. Med. 365, 378–379 (2011).
Garcia-Aguirre, G., Vanzinni-Zago, V. & Quiroz-Mercado, H. Growth of Scytalidium sp. in a counterfeit bevacizumab bottle. Indian J. Ophthalmol. 61, 523–525 (2013).
Wang, F. et al. Acute intraocular inflammation caused by endotoxin after intravitreal injection of counterfeit bevacizumab in Shanghai, China. Ophthalmology 120, 355–361 (2013).
Mackey, T. K. & Liang, B. A. The global counterfeit drug trade: patient safety and public health risks. J. Pharm. Sci. 100, 4571–4579 (2011).
Almuzaini, T., Sammons, H. & Choonara, I. Substandard and falsified medicines in the UK: a retrospective review of drug alerts (2001–2011). BMJ Open 3, e002924 (2013).
Gostin, L. O., Buckley, G. J. & Kelley, P. W. Stemming the global trade in falsified and substandard medicines. JAMA 309, 1693–1694 (2013).
Karunamoorthi, K. The counterfeit anti-malarial is a crime against humanity: a systematic review of the scientific evidence. Malar. J. 13, 209 (2014).
Newton, P. N., Green, M. D. & Fernández, F. M. Impact of poor-quality medicines in the 'developing' world. Trends Pharmacol. Sci. 31, 99–101 (2010).
Nayyar, G. M., Breman, J. G., Newton, P. N. & Herrington, J. Poor-quality antimalarial drugs in southeast Asia and sub-Saharan Africa. Lancet Infect. Dis. 12, 488–496 (2012).
Mackey, T. K. Global health diplomacy and the governance of counterfeit medicines: a mapping exercise of institutional approaches. Journal of Health Diplomacy [online], (2013).
Rosenthal, E. T. The 'gray market' raises concerns about cost, safety, and ethics. J. Natl Cancer Inst. 104, 168–170 (2012).
Woodward, C. Prices gone wild: grey market 'scalpers' scoring windfall in American drug market. CMAJ 184, E119–E120 (2012).
Forman, R. F. Availability of opioids on the Internet. JAMA 290, 889 (2003).
Liang, B. A. & Mackey, T. K. Online availability and safety of drugs in shortage: a descriptive study of internet vendor characteristics. J. Med. Internet Res. 14, e27 (2012).
Liang, B. A. & Mackey, T. K. Vaccine shortages and suspect online pharmacy sellers. Vaccine 30, 105–108 (2012).
Mackey, T. K., Liang, B. A. & Strathdee, S. A. Digital social media, youth, and nonmedical use of prescription drugs: the need for reform. J. Med. Internet Res. 15, e143 (2013).
Orizio, G. et al. 'Save 30% if you buy today'. Online pharmacies and the enhancement of peripheral thinking in consumers. Pharmacoepidemiol. Drug Saf. 19, 970–976 (2010).
CBC News. Canadadrugs.com's wholesale licence suspended [online], (2014).
Mackey, T. K. & Liang, B. A. Pharmaceutical digital marketing and governance: illicit actors and challenges to global patient safety and public health. Global Health 9, 45 (2013).
Brookings Institute. Reducing the Threat of Counterfeit and Unapproved Drugs in Clinical Settings [online], (2013).
Crinò, L. et al. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncol. 11, 733–740 (2010).
Hurwitz, H. & Saini, S. Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events. Semin. Oncol. 33, S26–S34 (2006).
Saif, M. W. Managing bevacizumab-related toxicities in patients with colorectal cancer. J. Support. Oncol. 7, 245–251 (2009).
Hershman, D. L. et al. Contraindicated use of bevacizumab and toxicity in elderly patients with cancer. J. Clin. Oncol. 31, 3592–3599 (2013).
Moisee, K. Cancer Patients Furious Over Counterfeit Avastin. ABC News [online], (2012).
US Food and Drug Administration. Drug Supply Chain Security Act (DSCSA) [online], (2013).
Outterson, K. The Drug Quality and Security Act—mind the gaps. N. Engl. J. Med. 370, 97–99 (2014).
US Food and Drug Administration. Guidance for Industry: Drug Supply Chain Security Act Implementation: Identification of Suspect Product and Notification [online], (2014).
Bansal, D., Malla, S., Gudala, K. & Tiwari, P. Anti-counterfeit technologies: a pharmaceutical industry perspective. Sci. Pharm. 81, 1–13 (2013).
Yukhananov, A. Congress fails to agree on national drug trace plan. Reuters [online], (2012).
Barlas, S. Track-and-trace drug verification: FDA plans new national standards, pharmacies tread with trepidation. PT 36, 203–231 (2011).
Mackey, T. K. & Liang, B. A. Combating healthcare corruption and fraud with improved global health governance. BMC Int. Health Hum. Rights 12, 23 (2012).
Yip, W. & Mahal, A. The health care systems of China and India: performance and future challenges. Health Affairs 27, 921–932 (2008).
Gautam, C. S., Utreja, A. & Singal, G. L. Spurious and counterfeit drugs: a growing industry in the developing world. Postgrad. Med. J. 85, 251–256 (2009).
Congressman Patrick Meehan, Representing the 7th District of Pennsylvania. Meehan Bill to Crackdown on Counterfeit Rx Drug Trafficking Passes House [online], (2012).
[No authors listed] Shortages of cancer drugs in the USA. Lancet Oncol. 12, 313 (2011).
Gatesman, M. L. & Smith, T. J. The shortage of essential chemotherapy drugs in the United States. N. Engl. J. Med. 365, 1653–1655 (2011).
Montero, A. J. & Vogel, C. Fighting fire with fire: rekindling the bevacizumab debate. N. Engl. J. Med. 366, 374–375 (2012).
Kolata, G. & Pollack, A. The Evidence Gap: Costly Cancer Drug Offers Hope, but Also a Dilemma. The New York Times [online], (2008).
Jirillo, A., Vascon, F. & Giacobbo, M. Bevacizumab in advanced cancer, too much or too little? Ann. Oncol. 19, 1817–1818 (2008).
Berkrot, B. Roche's Genentech defends supply shift for top cancer drugs. Yahoo Finance [online], (2014).
Kelly, R. J. & Smith, T. J. Delivering maximum clinical benefit at an affordable price: engaging stakeholders in cancer care. Lancet Oncol. 15, e112–e118 (2014).
Mileshkin, L. & Sullivan, D. Access to expensive anti-cancer drugs. J. Law Med. 19, 232–243 (2011).
Essential Medicines and Health Products Information Portal. Promoting Access to Medical Technologies and Innovation. Intersections Between Public Health, Intellectual Property and Trade [online], (2013).
Mackey, T. K. & Liang, B. A. Promoting global health: utilizing WHO to integrate public health, innovation and intellectual property. Drug Discov. Today 17, 1254–1257 (2012).
T.K.M. is the recipient of an American Cancer Society Institutional Research Grant (70-002) provided through the Moores Cancer Center, University of California, San Diego, CA, USA, that also provided support for R.C. T.K.M. also thanks the Engelberg Center for Health Care Reform at the Brookings Institute for his invitation to the Expert Workshop “Reducing the threat of counterfeit and unapproved drugs in clinical settings” on 19 July 2013.
T.K.M. and B.A.L. are reimbursed for travel to one Partnership for Safe Medicines annual conference each year. T.K.M. is also a non-compensated member of the academic advisory panel of the Alliance for Safe Online Pharmacies. R.C. and C.G. declare no competing interests.
About this article
Cite this article
Mackey, T., Cuomo, R., Guerra, C. et al. After counterfeit Avastin®—what have we learned and what can be done?. Nat Rev Clin Oncol 12, 302–308 (2015). https://doi.org/10.1038/nrclinonc.2015.35
International Journal of System Assurance Engineering and Management (2022)
Targeted Oncology (2017)
DARU Journal of Pharmaceutical Sciences (2015)